Targeting the kappa opioid receptor for analgesia and antitumour effects Editorial
| Authors: | Lambert, D. G.; Mincer, J. S. |
| Title: | Targeting the kappa opioid receptor for analgesia and antitumour effects |
| Abstract: | Kappa opioid (KOP) receptor agonists have analgesic actions in a range of models, but central side-effects can limit their utility. In addition, non-analgesic actions of opioid receptors are receiving significant research interest. A recent article reports that high KOP receptor expression in glioma tissue correlates with improved survival and that KOP receptor agonism further promotes apoptosis of glioma cells through regulation of the p38 MAPK oncogenic pathway. This suggests that KOP receptor ligands could be developed as chemotherapeutic adjuncts in addition to their use as analgesics. © 2024 British Journal of Anaesthesia |
| Keywords: | immunohistochemistry; cancer survival; protein expression; gene mutation; nonhuman; mitogen activated protein kinase p38; protein targeting; editorial; antineoplastic activity; glioblastoma; ligand; cyclin dependent kinase inhibitor 2a; opioid; analgesia; colon adenocarcinoma; short hairpin rna; immunocompetent cell; analgesic agent; clear cell renal cell carcinoma; non small cell lung cancer; kappa opiate receptor; mapk signaling; butorphanol; human; kappa opioid receptor; tumour biology; nalfurafine |
| Journal Title: | British Journal of Anaesthesia |
| Volume: | 134 |
| Issue: | 3 |
| ISSN: | 0007-0912 |
| Publisher: | Oxford University Press |
| Date Published: | 2025-03-01 |
| Start Page: | 646 |
| End Page: | 648 |
| Language: | English |
| DOI: | 10.1016/j.bja.2024.10.014 |
| PUBMED: | 39779420 |
| PROVIDER: | scopus |
| PMCID: | PMC11867103 |
| DOI/URL: | |
| Notes: | The MSK Cancer Center Support Grant (P30 CA008748) is acknowledge in the PDF -- Corresponding authors is MSK author: Joshua S. Mincer -- Source: Scopus |
